BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bitzan M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney International 2009;75:S62-6. [DOI: 10.1038/ki.2008.624] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Ridel C, Kissling S, Mesnard L, Hertig A, Rondeau É. Échanges plasmatiques en néphrologie : techniques et indications. Néphrologie & Thérapeutique 2017;13:43-55. [DOI: 10.1016/j.nephro.2016.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Ritchie JM. Animal Models of Enterohemorrhagic Escherichia coli Infection. Microbiol Spectr 2014;2:EHEC-0022-2013. [PMID: 26104195 DOI: 10.1128/microbiolspec.EHEC-0022-2013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
3 Fernández-Brando RJ, Bentancor LV, Mejías MP, Ramos MV, Exeni A, Exeni C, Laso Mdel C, Exeni R, Isturiz MA, Palermo MS. Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. PLoS One 2011;6:e19136. [PMID: 21559455 DOI: 10.1371/journal.pone.0019136] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
4 Ullrich S, Bremer P, Neumann-Grutzeck C, Otto H, Rüther C, von Seydewitz CU, Meyer GP, Ahmadi-Simab K, Röther J, Hogan B, Schwenk W, Fischbach R, Caselitz J, Puttfarcken J, Huggett S, Tiedeken P, Pober J, Kirkiles-Smith NC, Hagenmüller F. Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS One 2013;8:e55278. [PMID: 23460784 DOI: 10.1371/journal.pone.0055278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
5 Ivarsson ME, Leroux J, Castagner B. Therapien gegen Bakterientoxine. Angew Chem 2012;124:4098-121. [DOI: 10.1002/ange.201104384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
7 Luz D, Gómez FD, Ferreira RL, Melo BS, Guth BEC, Quintilio W, Moro AM, Presta A, Sacerdoti F, Ibarra C, Chen G, Sidhu SS, Amaral MM, Piazza RMF. The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody. Toxins (Basel) 2021;13:825. [PMID: 34822608 DOI: 10.3390/toxins13110825] [Reference Citation Analysis]
8 Castillo DS, Rey Serantes DA, Melli LJ, Ciocchini AE, Ugalde JE, Comerci DJ, Cassola A. A recombinant O-polysaccharide-protein conjugate approach to develop highly specific monoclonal antibodies to Shiga toxin-producing Escherichia coli O157 and O145 serogroups. PLoS One 2017;12:e0182452. [PMID: 28981517 DOI: 10.1371/journal.pone.0182452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
9 Zoja C, Locatelli M, Pagani C, Corna D, Zanchi C, Isermann B, Remuzzi G, Conway EM, Noris M. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. J Immunol 2012;189:3661-8. [PMID: 22942429 DOI: 10.4049/jimmunol.1102118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
10 Bertholet-thomas A, Ranchin B, King L, Bacchetta J, Belot A, Gillet Y, Collardeau-frachon S, Cochat P. Syndrome hémolytique et urémique post-diarrhéique : Quand y penser ? Quel suivi ? Archives de Pédiatrie 2011;18:823-30. [DOI: 10.1016/j.arcped.2011.04.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Blount ZD. The unexhausted potential of E. coli. Elife 2015;4. [PMID: 25807083 DOI: 10.7554/eLife.05826] [Cited by in Crossref: 149] [Cited by in F6Publishing: 58] [Article Influence: 21.3] [Reference Citation Analysis]
12 Bergan J, Skotland T, Lingelem AB, Simm R, Spilsberg B, Lindbäck T, Sylvänne T, Simolin H, Ekroos K, Sandvig K. The ether lipid precursor hexadecylglycerol protects against Shiga toxins. Cell Mol Life Sci 2014;71:4285-300. [PMID: 24740796 DOI: 10.1007/s00018-014-1624-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
13 Karve SS, Weiss AA. Glycolipid binding preferences of Shiga toxin variants. PLoS One 2014;9:e101173. [PMID: 24983355 DOI: 10.1371/journal.pone.0101173] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
14 Imdad A, Mackoff SP, Urciuoli DM, Syed T, Tanner-Smith EE, Huang D, Gomez-Duarte OG. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;7:CD012997. [PMID: 34219224 DOI: 10.1002/14651858.CD012997.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Hunt JM. Shiga toxin-producing Escherichia coli (STEC). Clin Lab Med 2010;30:21-45. [PMID: 20513540 DOI: 10.1016/j.cll.2009.11.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
16 Wu SY, Park GY, Kim SH, Hulme J, An SS. Diminazene aceturate: an antibacterial agent for Shiga-toxin-producing Escherichia coli O157:H7. Drug Des Devel Ther 2016;10:3363-78. [PMID: 27789937 DOI: 10.2147/DDDT.S114832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
18 Gallegos KM, Conrady DG, Karve SS, Gunasekera TS, Herr AB, Weiss AA. Shiga toxin binding to glycolipids and glycans. PLoS One 2012;7:e30368. [PMID: 22348006 DOI: 10.1371/journal.pone.0030368] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
19 Hostetter SJ, Helgerson AF, Paton JC, Paton AW, Cornick NA. Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome. BMC Res Notes 2014;7:331. [PMID: 24890228 DOI: 10.1186/1756-0500-7-331] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177. [PMID: 20568098 DOI: 10.1002/jca.20240] [Cited by in Crossref: 366] [Cited by in F6Publishing: 303] [Article Influence: 30.5] [Reference Citation Analysis]
21 Keir LS. Shiga Toxin Associated Hemolytic Uremic Syndrome. Hematology/Oncology Clinics of North America 2015;29:525-39. [DOI: 10.1016/j.hoc.2015.01.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
22 Cheng LW, Henderson TD, Patfield S, Stanker LH, He X. Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodies. Toxins (Basel) 2013;5:1845-58. [PMID: 24152988 DOI: 10.3390/toxins5101845] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
23 Chromek M, Arvidsson I, Karpman D. The antimicrobial peptide cathelicidin protects mice from Escherichia coli O157: H7-mediated disease. PLoS One. 2012;7:e46476. [PMID: 23077510 DOI: 10.1371/journal.pone.0046476] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
24 Grisaru S, Morgunov MA, Samuel SM, Midgley JP, Wade AW, Tee JB, Hamiwka LA. Acute renal replacement therapy in children with diarrhea-associated hemolytic uremic syndrome: a single center 16 years of experience. Int J Nephrol 2011;2011:930539. [PMID: 21716936 DOI: 10.4061/2011/930539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
25 Ozaki M, Kang Y, Tan YS, Pavlov VI, Liu B, Boyle DC, Kushak RI, Skjoedt MO, Grabowski EF, Taira Y, Stahl GL. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int 2016;90:774-82. [PMID: 27378476 DOI: 10.1016/j.kint.2016.05.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
26 Ivarsson ME, Leroux JC, Castagner B. Targeting bacterial toxins. Angew Chem Int Ed Engl 2012;51:4024-45. [PMID: 22441768 DOI: 10.1002/anie.201104384] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
27 Bitzan M, Poole R, Mehran M, Sicard E, Brockus C, Thuning-Roberson C, Rivière M. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 2009;53:3081-7. [PMID: 19414580 DOI: 10.1128/AAC.01661-08] [Cited by in Crossref: 56] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
28 Gao X, Wu H, Hao Z, Ji X, Lin X, Wang S, Liu Y. A multifunctional plasmonic chip for bacteria capture, imaging, detection, and in situ elimination for wound therapy. Nanoscale 2020;12:6489-97. [PMID: 32154542 DOI: 10.1039/d0nr00638f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
29 Nasrin T, Patra M, Escudey M, Das TK. Biosynthesized CdS nanoparticles disturb E. coli growth through reactive oxygen production. Microbial Pathogenesis 2019;135:103639. [DOI: 10.1016/j.micpath.2019.103639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Rojas RL, Gomes PA, Bentancor LV, Sbrogio-Almeida ME, Costa SO, Massis LM, Ferreira RC, Palermo MS, Ferreira LC. Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli. Clin Vaccine Immunol 2010;17:529-36. [PMID: 20147499 DOI: 10.1128/CVI.00495-09] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
31 Bauwens A, Betz J, Meisen I, Kemper B, Karch H, Müthing J. Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature. Cell Mol Life Sci 2013;70:425-57. [PMID: 22766973 DOI: 10.1007/s00018-012-1060-z] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
32 Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010;25:2231-40. [DOI: 10.1007/s00467-010-1522-1] [Cited by in Crossref: 127] [Cited by in F6Publishing: 114] [Article Influence: 10.6] [Reference Citation Analysis]
33 Wadehra A, Alkassis S. Atypical Hemolytic Uremic Syndrome in the Setting of Acute Clostridium difficile Colitis. Cureus 2021;13:e13244. [PMID: 33728192 DOI: 10.7759/cureus.13244] [Reference Citation Analysis]
34 Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial 2012;25:214-9. [PMID: 22309967 DOI: 10.1111/j.1525-139X.2011.01035.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
35 Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010;56:1168-74. [PMID: 20843591 DOI: 10.1053/j.ajkd.2010.06.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
36 Wadl M, Müller-wiefel D, Stark K, Fruth A, Karch H, Werber D. Enteropathisches hämolytisch-urämisches Syndrom: Sporadischer Einzelfall oder Teil eines Krankheitsausbruchs? Monatsschr Kinderheilkd 2011;159:152-60. [DOI: 10.1007/s00112-010-2272-7] [Reference Citation Analysis]
37 Sreerohini S, Balakrishna K, Parida M. Oral immunization of mice with Lactococcus lactis expressing Shiga toxin truncate confers enhanced protection against Shiga toxins of Escherichia coli O157:H7 and Shigella dysenteriae. APMIS 2019;127:671-80. [PMID: 31344276 DOI: 10.1111/apm.12983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zumbrun SD, Hanson L, Sinclair JF, Freedy J, Melton-Celsa AR, Rodriguez-Canales J, Hanson JC, O'Brien AD. Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide. Infect Immun 2010;78:4488-99. [PMID: 20732996 DOI: 10.1128/IAI.00620-10] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
39 Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009;27 Suppl 6:G38-46. [PMID: 20006139 DOI: 10.1016/j.vaccine.2009.09.105] [Cited by in Crossref: 119] [Cited by in F6Publishing: 104] [Article Influence: 9.9] [Reference Citation Analysis]
40 Shahrbabak SS, Khodabandehlou Z, Shahverdi AR, Skurnik M, Ackermann HW, Varjosalo M, Yazdi MT, Sepehrizadeh Z. Isolation, characterization and complete genome sequence of PhaxI: a phage of Escherichia coli O157 : H7. Microbiology (Reading) 2013;159:1629-38. [PMID: 23676434 DOI: 10.1099/mic.0.063776-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
41 Chromek M. The role of the antimicrobial peptide cathelicidin in renal diseases. Pediatr Nephrol 2015;30:1225-32. [PMID: 25159719 DOI: 10.1007/s00467-014-2895-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
42 Grisaru S. Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis 2014;7:231-9. [PMID: 24966691 DOI: 10.2147/IJNRD.S41837] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
43 Bai X, Shen A, Hu J. A sensitive SERS-based sandwich immunoassay platform for simultaneous multiple detection of foodborne pathogens without interference. Anal Methods 2020;12:4885-91. [DOI: 10.1039/d0ay01541e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
44 Grisaru S, Midgley JP, Hamiwka LA, Wade AW, Samuel SM. Diarrhea-associated hemolytic uremic syndrome in southern Alberta: A long-term single-centre experience. Paediatr Child Health 2011;16:337-40. [PMID: 22654544 DOI: 10.1093/pch/16.6.337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
45 Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 2013;25:209-15. [PMID: 23399570 DOI: 10.1097/MOP.0b013e32835df48a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
46 Xiong H, Guo B, Gan Z, Song D, Lu Z, Yi H, Wu Y, Wang Y, Du H. Butyrate upregulates endogenous host defense peptides to enhance disease resistance in piglets via histone deacetylase inhibition. Sci Rep 2016;6. [DOI: 10.1038/srep27070] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
47 Zoja C, Buelli S, Morigi M. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 2019;34:379-88. [PMID: 29214442 DOI: 10.1007/s00467-017-3850-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
48 Keir LS, Langman CB. Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis. Transfus Apher Sci 2016;54:203-11. [PMID: 27156109 DOI: 10.1016/j.transci.2016.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
49 Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187:172-180. [PMID: 21642543 DOI: 10.4049/jimmunol.1100491] [Cited by in Crossref: 160] [Cited by in F6Publishing: 141] [Article Influence: 14.5] [Reference Citation Analysis]
50 Kessler CS, Khan BA, Lai-miller K. Thrombotic Thrombocytopenic Purpura: A Hematological Emergency. The Journal of Emergency Medicine 2012;43:538-44. [DOI: 10.1016/j.jemermed.2012.01.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
51 Lingwood C. Therapeutic Uses of Bacterial Subunit Toxins. Toxins (Basel) 2021;13:378. [PMID: 34073185 DOI: 10.3390/toxins13060378] [Reference Citation Analysis]
52 Shringi S, Sheng H, Potter AA, Minnich SA, Hovde CJ, Besser TE. Repeated Oral Vaccination of Cattle with Shiga Toxin-Negative Escherichia coli O157:H7 Reduces Carriage of Wild-Type E. coli O157:H7 after Challenge. Appl Environ Microbiol 2021;87:e02183-20. [PMID: 33158889 DOI: 10.1128/AEM.02183-20] [Reference Citation Analysis]
53 Henrique IDM, Sacerdoti F, Ferreira RL, Henrique C, Amaral MM, Piazza RMF, Luz D. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives. Front Cell Infect Microbiol 2022;12:825856. [DOI: 10.3389/fcimb.2022.825856] [Reference Citation Analysis]